Yield Optimization in Viral Vector Manufacturing

Driving down the cost of viral vector development to make these life-changing therapies more accessible

Viral vectors are more than a vehicle for a payload – their ability to target specific cells has made them one of the most promising treatment modalities to emerge in recent years. But the specificity enabled by this tropism has created complexities impacting their scale-up.

Ensuring optimal yield for engineered viral vectors is crucial to ensuring their eventual commercial viability. Despite this, it can be easy to overlook the factors that impact yield performance early enough, resulting in suboptimal yields, rework, and the potential scrapping of an otherwise promising therapeutic. Frequently, issues related to yield are not uncovered until toxicology testing has already commenced, and considerable time and cost investment has already been leveraged toward a transgene that, while effective, is production-inefficient.

Download to learn about variables that impact yield optimization for viral vectors.